Citigroup believes Teva's appointment of Timothy Wright as development, strategy and innovation head suggests a material, potentially transformative, transaction, is not off the table for the company. It points out the press release highlighted Wright's experience in "leading the transformation of large companies," and added that it’s a "transformative time for both the company and the industry." Citi views Teva's balance sheet as under-levered and says the company needs deals to diversify away from Copaxone. It keeps a Buy rating on the stock with a $70 price target.

Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."